QMSR Evidence Rules for U.S. Medical Device Preemption

When a medical device injures someone, federal law under 21 U.S.C. §360k can bar state-law claims that impose requirements different from or in addition to FDA requirements. Under Riegel v. Medtronic, claims against devices that went through Premarket Approval (PMA) face strong express preemption. Devices cleared through the 510(k) pathway generally do not get that same shield, a distinction rooted in Medtronic v. Lohr. The FDA’s 2026 Quality Management System Regulation changes how manufacturers document compliance, but it does not touch this statutory standard.

TL;DR:

• Devices approved through the PreMarket Approval process face strong federal preemption, especially when a state verdict conflicts with the FDA’s design or safety standards.
• Claims alleging violation of FDA-approved specifications generally survive as parallel claims, while those challenging device design or labeled warnings often get preempted.
• The 2026 implementation of the FDA’s Quality Management System Regulation shifts compliance documentation standards but does not alter preemption rules.
• Manufacturers should carefully document all design and labeling changes, especially post-approval modifications, to support potential impossibility defenses or avoid preemption-based liability.
• Early preservation of FDA correspondence, approval files, and device records enhances the chances of overcoming preemption defenses in litigation.

Table of Contents

• Preemption defined: express versus implied, impossibility versus obstacle
• The preemption trilogy: Buckman, Lohr, and Riegel
• Operational risks manufacturers face: labeling, design, and controls
• How plaintiffs and defendants build claims around preemption
• A checklist for how courts actually decide preemption
• The QMSR update and what it changes for litigation evidence
• Why early legal guidance matters more than most people expect
• Getting help with a defective device claim in Indiana, Michigan, or New Mexico
• Sources
• FAQ

Preemption defined: express versus implied, impossibility versus obstacle

Federal preemption comes from the Supremacy Clause, and courts sort it into a few recognized categories. According to the Legal Information Institute, preemption is generally divided into express preemption, where Congress states directly that federal law displaces state law, and implied or conflict preemption, where the displacement is inferred from how the two laws interact.

Conflict preemption itself splits into two working tests. Impossibility preemption applies when a party literally cannot comply with both state and federal law at the same time, such as when federal rules forbid a specific labeling change that state tort law would otherwise require. Obstacle preemption applies more broadly: it asks whether the state law, even if technically compliable, stands as an obstacle to the purposes Congress had in mind when it created the federal scheme.

Courts weighing these questions in health and safety contexts often start from what’s called a presumption against preemption, the idea that Congress does not lightly displace a state’s traditional police powers over matters like tort liability and consumer protection. The Constitution Annotated discussion hosted by LII notes that this presumption’s strength varies by context and can give way when Congress’s intent to preempt is clear. In medical device cases, that intent is unusually explicit: §360k contains express preemption language that Congress wrote directly into the statute, which is part of why device litigation looks different from ordinary product liability disputes.

A few device-specific examples make the categories concrete:

• Express preemption: A state jury verdict finding a PMA-approved pacemaker defectively designed, when the design matches exactly what FDA approved, directly imposes a requirement different from the federal one.
• Impossibility preemption: A manufacturer cannot simultaneously comply with a state order to add a warning FDA has not approved and a federal rule prohibiting labeling changes without agency sign-off.
• Obstacle preemption: A state law effectively second-guessing FDA’s risk-benefit approval decision interferes with the federal goal of centralizing device safety judgments in one expert agency.
• No preemption (parallel claim): A claim that a manufacturer violated its own FDA-approved specifications, rather than asking a court to impose new ones, tracks federal requirements instead of adding to them.

These distinctions decide, case by case, whether a plaintiff gets into court at all. The next question is where these rules actually live in the federal code and regulations.

The preemption trilogy: Buckman, Lohr, and Riegel

Three Supreme Court decisions form the backbone of medical device preemption doctrine, and together they draw the line between claims that survive and claims that don’t.

Buckman Co. v. Plaintiffs’ Legal Committee (2001) came first in the modern sequence and established implied preemption in a narrower but consequential context. According to the opinion text, the Court held that state-law claims alleging fraud on the FDA, essentially, that a manufacturer lied to the agency to get a device cleared, are impliedly preempted because policing fraud against a federal agency is a task Congress assigned exclusively to that agency. Letting state juries second-guess what the FDA was told would create a conflict with the federal scheme, even without an explicit statutory preemption clause covering fraud claims.

Medtronic v. Lohr (1996) addressed the far more common 510(k) pathway, where devices reach market by showing substantial equivalence to an already-cleared predicate device rather than through the rigorous PMA review process. The Court held that because 510(k) clearance does not involve FDA’s independent judgment about the device’s safety and effectiveness in the way PMA approval does, most state tort claims against 510(k) devices are not preempted. This opinion is also where the “parallel claims” concept took root: a claim alleging a manufacturer violated its own FDA-cleared specifications runs parallel to federal requirements rather than adding new ones, and so it escapes preemption.

Riegel v. Medtronic (2008) then sharpened the rule for PMA devices specifically. As the case summary explains, the Court held that state-law claims challenging the safety or effectiveness of a device that went through the rigorous PMA process are generally preempted, because PMA approval itself constitutes a federal “requirement” specific to that device under §360k. A state jury verdict imposing a different standard, even a well-intentioned one, conflicts directly with what the FDA already decided.

When a jury verdict rests on a state duty that differs from what the FDA approved for a PMA device, that verdict itself becomes a preempted state requirement.

These three cases interact in a predictable pattern once you separate device pathway from claim type. PMA devices carry strong express preemption under Riegel, but plaintiffs can still bring parallel claims alleging violations of the manufacturer’s own FDA-approved specifications. 510(k) devices carry much weaker preemption protection under Lohr, since there’s no rigorous federal approval standard to conflict with. And claims resembling fraud on the agency itself, regardless of pathway, run into Buckman’s implied preemption bar.

• PMA devices: strong express preemption per Riegel, with a narrow parallel-claim escape valve.
• 510(k) devices: limited preemption per Lohr, since substantial equivalence review is not the kind of specific federal requirement §360k contemplates.
• Fraud-on-the-FDA claims: impliedly preempted under Buckman regardless of device pathway.
• Parallel claims: the consistent exception litigators on both sides fight over, since state and federal circuits disagree on how precisely a complaint must track the federal violation to qualify.

Circuit splits on parallel claims are where much of the current litigation energy sits. Some courts require plaintiffs to plead with the specificity typical of fraud claims, essentially identifying exactly which federal requirement was violated and how. Others apply a more forgiving notice-pleading standard, letting general allegations of manufacturing deviations survive a motion to dismiss. Anyone litigating a PMA-device case needs to know which standard governs in the relevant circuit before drafting a complaint, since a wrongly pled parallel claim gets dismissed as an improper attempt to impose additional requirements.

Operational risks manufacturers face: labeling, design, and controls

Preemption doctrine is not just a courtroom concept. It shapes real compliance decisions manufacturers make long before litigation starts, and getting the pathway distinction wrong creates exposure on both regulatory and litigation fronts.

The PMA versus 510(k) distinction determines how much protection a company can expect if something goes wrong. A manufacturer that markets a PMA device but modifies its design or manufacturing process without a proper supplement risks losing its preemption defense entirely, since the protection Riegel offers depends on the device actually matching what FDA approved. A 510(k) manufacturer, meanwhile, should not assume any preemption shield at all and needs to treat state tort exposure as a live risk from day one.

Labeling changes deserve particular attention because they sit at the center of many impossibility defenses. The FDA’s Changes Being Effected (CBE) process allows certain labeling updates, typically ones that strengthen a warning, without prior agency approval, while other changes require notification and can only take effect after FDA review. A manufacturer that could have used CBE to add a warning but didn’t has a much weaker impossibility argument than one whose only option was full prior approval.

1. Confirm the pathway. Document whether a device is PMA-approved or 510(k)-cleared before assessing preemption exposure, since the two pathways carry very different legal protection.
2. Track every labeling change mechanism available. Know which warnings could have gone through CBE versus which required prior FDA sign-off, since that distinction often decides an impossibility defense.
3. Maintain design history files and complaint records under QMSR. These documents are frequently what separates a preempted claim from a viable parallel claim in court.
4. Audit manufacturing deviations against approved specifications regularly. A gap between actual production and the PMA-approved specification is exactly what plaintiffs look for in parallel-claim pleadings.

Pro Tip: Keep a running file that maps every post-approval design or labeling change to the specific FDA submission or notification that authorized it. That single document often decides a preemption motion faster than anything else in discovery.

How plaintiffs and defendants build claims around preemption

Preemption motions are frequently decided early, often at the motion to dismiss stage, which means both sides have to think about pleading strategy from the first draft of the complaint.

Plaintiffs’ counsel generally try to frame allegations as violations of the manufacturer’s own FDA-approved specifications rather than as claims that the device should have been designed or labeled differently than FDA approved. That framing is what keeps a parallel claim alive under Lohr’s logic. Common tactics include:

• Alleging specific manufacturing deviations documented in FDA warning letters or inspection reports, tying the state claim directly to a violation of an existing federal requirement.
• Pleading a failure to report adverse events as required by federal regulation, rather than arguing the device’s design itself was defective.
• Avoiding language that reads like a demand for a different label or design than what FDA approved, since that framing invites an express preemption motion.
• Requesting early discovery of FDA correspondence and inspection history before the preemption motion is fully briefed, since that evidence often determines whether the parallel claim has factual support.

Defense counsel, correspondingly, look to show that any state claim, however framed, ultimately asks for something different from or in addition to what FDA required. Strategies include highlighting that the alleged design flaw was expressly reviewed and approved during the PMA process, that no CBE or notification pathway existed for the change plaintiffs say should have happened, or that the claim as pled is functionally a fraud-on-the-FDA theory subject to Buckman.

Documents tend to decide these disputes long before trial. FDA correspondence, the PMA or 510(k) submission file, inspection reports, and the manufacturer’s own labeling-change history are usually what a court reviews when ruling on a preemption motion, which is why early case assessment on both sides should prioritize obtaining that record set as soon as possible.

A checklist for how courts actually decide preemption

Judges applying preemption doctrine tend to move through a consistent sequence, even though the outcome in any given case remains fact-specific.

• Step one: Identify the specific federal requirement that applies to the device, distinguishing a PMA approval (specific to that device) from general FDA regulations of broad applicability.
• Step two: Compare the state law duty the plaintiff invokes to that federal requirement, asking whether the state duty is “different from, or in addition to” the federal one.
• Step three: If the state duty tracks the federal requirement rather than adding to it, treat the claim as a permissible parallel claim.
• Step four: Apply impossibility analysis where relevant, asking whether the manufacturer could have complied with both duties simultaneously.
• Step five: Apply obstacle analysis where impossibility doesn’t resolve the question, asking whether the state claim undermines the purpose of the federal scheme even if technical compliance with both was possible.

Litigators on either side benefit from running through this sequence before filing, since a complaint or motion that skips a step tends to draw a quick and unfavorable ruling.

The QMSR update and what it changes for litigation evidence

The FDA’s Quality Management System Regulation took effect on February 2, 2026, and it represents the most significant change to device quality requirements in years. The rule harmonizes the prior Quality System Regulation with the international ISO 13485:2016 standard and introduces a risk-based inspection model under Compliance Program 7382.850, shifting how FDA prioritizes and conducts facility inspections.

A key figure to know: the QMSR’s effective date, February 2, 2026, marks the point at which manufacturers must operate under the harmonized standard rather than the legacy Quality System Regulation, and it changes the baseline documentation FDA inspectors and courts will expect going forward.

What changes in practice includes:

• Design controls, risk management files, and postmarket surveillance records now map to ISO 13485:2016’s structure, which changes how discovery requests should be worded and what document categories to request.
• Inspections under Compliance Program 7382.850 are risk-based rather than uniform, meaning some facilities see more frequent scrutiny and others see less, a distinction that can matter to establishing a manufacturer’s inspection history in litigation.
• FDA’s own materials describe the QMSR as a harmonization and modernization effort intended to simplify global compliance, not a change to the underlying safety standards devices must meet.

None of this alters the statutory preemption standard in §360k(a). The QMSR is a regulatory harmonization measure, and Congress, not FDA rulemaking, sets the preemption rule. What does change is the evidentiary landscape: the specific records, audit trails, and reporting formats that regulators and courts will look to when deciding whether a manufacturer complied with its own federal requirements, which is precisely the question that decides most parallel-claim disputes.

Why early legal guidance matters more than most people expect

Preemption doctrine rewards the side that moves first on documentation. In more than a decade of handling device and product liability claims, our experience is that cases won or lost on preemption grounds are usually decided by which party assembled the FDA correspondence, the approval history, and the design change record before the other side did. Waiting until after a motion to dismiss is filed to start gathering that material is often too late.

If you’ve been injured by a device and you’re unsure whether federal law limits your options, the most useful thing you can do immediately is preserve everything: the device itself if it was explanted, the implant card or identifier, any FDA-related paperwork you received, and your full medical records. A conversation with an attorney early in that process, even before you’ve decided whether to pursue a claim, can clarify whether the device went through PMA or 510(k) review and what that means for your case’s viability.

Adam

Getting help with a defective device claim in Indiana, Michigan, or New Mexico

Preemption law adds a layer of complexity that most injured people never expected to face when they agreed to a medical device. We evaluate that complexity for you from the first conversation, at no cost, so you know where your case stands before you commit to anything.

A free case evaluation gives you a direct read on whether your device claim is likely to face a preemption defense and what evidence will matter most if it does. Bring what you have: medical records, the device’s model and lot number if available, any correspondence you received about a recall or safety notice, and a timeline of when symptoms or complications began. Our team looks at the device’s approval pathway early, since that single fact often shapes the entire strategy for your case. We work on a contingency basis for device and product liability claims across Indiana, Michigan, and New Mexico: no fee unless we recover compensation for you. If you’re weighing whether pursuing a claim makes sense, start with a conversation, not a decision.

This article is general information, not a substitute for advice from a qualified lawyer. Consult a qualified legal professional about your own circumstances before acting on anything here.

Sources

The operative language sits in 21 U.S.C. §360k(a), part of the Medical Device Amendments of 1976. The statute provides that no state may establish or continue in effect any requirement related to device safety or effectiveness that is “different from, or in addition to” a federal requirement applicable to that device, and that relates to safety or effectiveness. The word “requirement” has done enormous work in the case law that followed, since courts had to decide whether a common-law jury verdict even counts as a state “requirement” in the first place. The Supreme Court eventually said yes, a verdict can impose a requirement just as surely as a statute can.

Not every state rule is preempted, though. 21 CFR Part 808, available on eCFR, lays out a process for state or local governments to apply for exemptions from preemption, and it clarifies that requirements of general applicability, rules that aren’t specific to medical devices, generally survive. A state’s basic negligence or contract law, for instance, is not automatically wiped out simply because a device is involved.

• Riegel v. Medtronic, summary and analysis

A key figure to know: the FDA’s Quality Management System Regulation took effect on February 2, 2026, replacing the prior Quality System Regulation and aligning U.S. requirements with the international ISO 13485:2016 standard. This matters to litigators because QMSR records, design history files, and risk management documentation are frequently the exact evidence courts examine when deciding whether a claim is a preempted attack on FDA’s judgment or a permissible parallel claim about a manufacturer’s own compliance failures.

FAQ

What are the three types of preemption in the United States?

Preemption generally divides into express preemption, where a statute states directly that it displaces state law, and implied preemption, which includes conflict preemption in its two forms: impossibility and obstacle preemption, according to the Legal Information Institute. Some analyses count field preemption as a distinct third category, though device litigation almost always turns on express and conflict preemption.

What are the key changes in medical device regulations for 2026?

The most significant regulatory change is the FDA’s Quality Management System Regulation, effective February 2, 2026, which aligns U.S. device quality requirements with the ISO 13485:2016 international standard. It also introduces a risk-based inspection approach under Compliance Program 7382.850, changing how FDA prioritizes facility inspections without altering the statutory preemption standard.

What are some examples of federal preemption?

Medical device law offers one of the clearest examples: under Riegel v. Medtronic, state tort claims challenging a PMA-approved device’s safety or design are generally preempted because they conflict with FDA’s own approval decision. Another example is Buckman v. Plaintiffs’ Legal Committee, where fraud-on-the-FDA claims were held impliedly preempted because policing agency fraud is a federal responsibility.

How do courts decide preemption cases?

Courts typically identify the specific federal requirement that applies to the device, then compare it to the state law duty the plaintiff invokes, asking whether the state duty is different from or in addition to the federal one. If the claim instead alleges the manufacturer violated its own FDA-approved specifications, courts often treat it as a permissible parallel claim rather than a preempted one.

Recommended

• Defective Medical Device Lawyers